Skip to content
Adrienne Monson – Lifestyle
Author:
Highlight Therapeutics
Highlight Therapeutics Presents Positive Phase 2b Topline Results of Intralesional BO-112 in Localized Basal Cell Carcinoma as a Late-Breaker at EADV
September 30, 2026